{"id":519889,"date":"2021-07-29T08:18:10","date_gmt":"2021-07-29T12:18:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/"},"modified":"2021-07-29T08:18:10","modified_gmt":"2021-07-29T12:18:10","slug":"strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/","title":{"rendered":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue"},"content":{"rendered":"
\n

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (\u201cStrongbridge<\/strong>\u201d), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on\u00a0July 28, 2021, Strongbridge’s issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of\u00a0$0.01\u00a0per share. Strongbridge’s ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97.<\/p>\n

Strongbridge confirms that, as of the close of business on\u00a0July 28, 2021, there were outstanding 2,747,191 restricted share units (the \u201cStrongbridge Restricted Share Units<\/strong>\u201d) and 8,226,117 options to purchase Strongbridge ordinary shares (the “Strongbridge Share Options<\/strong>“) granted by Strongbridge. Upon vesting, each Strongbridge Restricted Share Unit entitles the holder to receive one Strongbridge ordinary share and each Strongbridge Share Option entitles the holder to purchase one Strongbridge ordinary share at the applicable exercise price.<\/p>\n

Strongbridge also confirms that as of the close of business on\u00a0July 28, 2021, Strongbridge has 7,368,033 warrants outstanding (the \u201cStrongbridge Warrants<\/strong>\u201d) and 4,464,285 ordinary shares will be issued upon the conversion of the portion of Strongbridge’s debt that is convertible. Upon exercise, each Strongbridge Warrant entitles the holder to receive one ordinary share.<\/p>\n

\n About Strongbridge Biopharma plc <\/strong>\n <\/p>\n

Strongbridge is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV\u00ae (levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The company’s rare neuromuscular franchise includes KEVEYIS\u00ae (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in\u00a0the United States.<\/p>\n

\n
\n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION<\/em>
\n <\/strong>\n <\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Corporate and Media Relations<\/strong>
\n
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com<\/strong><\/a><\/p>\n

\n Investor Relations<\/strong>
\n
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com<\/strong><\/a><\/p>\n

\n No Offer or Solicitation<\/strong><\/p>\n

This communication is for information purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition (the \u201cAcquisition<\/strong>\u201d) of Strongbridge by Xeris Pharmaceuticals, Inc. (\u201cXeris<\/strong>\u201d) by means of a scheme of arrangement under Irish law (the \u201cScheme<\/strong>\u201d) or the other transactions contemplated by the Transaction Agreement, dated\u00a0May 24, 2021, among Strongbridge, Xeris,\u00a0Xeris Biopharma Holdings, Inc.\u00a0(\u201cHoldCo<\/strong>\u201d) and\u00a0Wells MergerSub, Inc.\u00a0(collectively, the \u201cTransaction<\/strong>\u201d), nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this communication is not an offer of securities for sale into\u00a0the United States. No offer of securities shall be made in\u00a0the United States\u00a0absent registration under the Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. The Acquisition will be made solely by means of the Scheme Document, which contains the full terms and conditions of the Acquisition, including details of how Strongbridge shareholders may vote in respect of the Acquisition.<\/p>\n

\n Important Additional Information and Where to Find It<\/strong>\n <\/p>\n

Strongbridge, Xeris and\u00a0HoldCo\u00a0have prepared and filed with the\u00a0SEC\u00a0a preliminary joint proxy statement\/prospectus on\u00a0July 2, 2021 and Amendment No. 1 thereto on July 28, 2021\u00a0(File No. 333-257642) which also constitutes a prospectus with respect to the\u00a0HoldCo\u00a0shares of common stock (\u201cHoldCo Shares<\/strong>\u201d) to be issued pursuant to the Transaction. The joint proxy statement\/prospectus also contains the Scheme Document and further information relating to the implementation of the Transaction, the full terms and conditions of the Transaction (including the Scheme), notices of the Strongbridge Special Meetings and the Xeris Special Meeting (each as defined in the joint proxy statement\/prospectus) and information on HoldCo Shares. Strongbridge and Xeris may also file other documents with the\u00a0SEC\u00a0regarding the Transaction. This communication is not a substitute for the joint proxy statement\/prospectus or any other document which Strongbridge, Xeris or\u00a0HoldCo\u00a0may file with the\u00a0SEC.<\/p>\n

The joint proxy statement\/prospectus, as well as Strongbridge\u2019s and Xeris\u2019 other public filings with the\u00a0SEC, may be obtained without charge at the SEC\u2019s website at\u00a0www.sec.gov<\/strong><\/a>\u00a0and, in the case of Strongbridge\u2019s filings, at Strongbridge\u2019s website at\u00a0www.strongbridgebio.com<\/strong><\/a>\u00a0and, in the case of Xeris\u2019 filings, at Xeris\u2019 website at\u00a0www.xerispharma.com<\/strong><\/a>.<\/p>\n

INVESTORS, STRONGBRIDGE SHAREHOLDERS AND XERIS STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT\/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE\u00a0SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION.<\/p>\n

Any vote in respect of resolutions to be proposed at the Strongbridge Special Meetings to approve the Acquisition, the Scheme or related matters, or other responses in relation to the Acquisition, should be made only on the basis of the information contained in the joint proxy statement\/prospectus (including the Scheme Document). Similarly, any decision in respect of resolutions to be proposed at the Xeris Special Meeting or any vote in respect of, or other response to, the Transaction, should be made only on the basis of the information contained in the joint proxy statement\/prospectus.<\/p>\n

\n Participants in the Solicitation<\/strong>\n <\/p>\n

Strongbridge, Xeris,\u00a0HoldCo\u00a0and their respective directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from their respective shareholders in connection with the Transaction. Information regarding the persons who may, under the rules of the\u00a0SEC, be deemed to be participants in the solicitation of shareholders in connection with the Transaction, including a description of their direct or indirect interests, which may be different from those of Strongbridge shareholders or Xeris stockholders generally, by security holdings or otherwise, are set forth in the joint proxy statement\/prospectus (which contains the Scheme Document) and will be set forth in any other relevant documents that are filed or will be filed with the\u00a0SEC\u00a0relating to the Transaction. Information regarding Strongbridge\u2019s directors and executive officers is contained in Strongbridge\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2020, filed with the\u00a0SEC\u00a0on\u00a0March 3, 2021, and its Proxy Statement on Schedule 14A, dated and filed with the\u00a0SEC\u00a0on\u00a0April 14, 2021. Information regarding Xeris\u2019 directors and executive officers is contained in Xeris\u2019 Annual Report on Form 10-K for the year ended\u00a0December 31, 2020, filed with the\u00a0SEC\u00a0on\u00a0March 9, 2021, and its Proxy Statement on Schedule 14A, dated and filed with the\u00a0SEC\u00a0on\u00a0April 29, 2021. You may obtain free copies of these documents using the sources indicated above.<\/p>\n

\n No Profit Forecast\/Asset Valuations<\/strong>\n <\/p>\n

No statement in this communication is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Strongbridge, Xeris or\u00a0HoldCo\u00a0as appropriate. No statement in this communication constitutes an asset valuation.<\/p>\n

\n Statement Required by the Irish Takeover Rules<\/strong>\n <\/p>\n

The directors of Strongbridge accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the directors of Strongbridge (who have taken all reasonable care to ensure such is the case), the information contained in this rep for which they respectively accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.<\/p>\n

\n Dealing Disclosure Requirements<\/strong>\n <\/p>\n

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, \u2018interested\u2019 (directly or indirectly) in 1% or more of any class of \u2018relevant securities\u2019 of Strongbridge or Xeris, all \u2018dealings\u2019 in any \u2018relevant securities\u2019 of Strongbridge or Xeris (including by means of an option in respect of, or a derivative referenced to, any such \u2018relevant securities\u2019) must be publicly disclosed by not later than 3:30 pm (New York time) on the \u2018business\u2019 day following the date of the relevant transaction. This requirement will continue until the date on which the Scheme becomes effective or on which the \u2018offer period\u2019 otherwise ends. If two or more persons cooperate on the basis of any agreement, either express or tacit, either oral or written, to acquire an \u2018interest\u2019 in \u2018relevant securities\u2019 of Strongbridge or Xeris, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.<\/p>\n

Under the provisions of Rule 8.1 of the Irish Takeover Rules, all \u2018dealings\u2019 in \u2018relevant securities\u2019 of Strongbridge by Xeris or \u2018relevant securities\u2019 of Xeris by Strongbridge, or by any party acting in concert with either of them, must also be disclosed by no later than 12 noon (New York time) on the \u2018business\u2019 day following the date of the relevant transaction.<\/p>\n

A disclosure table, giving details of the companies in whose \u2018relevant securities\u2019 \u2018dealings\u2019 should be disclosed, can be found on the Panel\u2019s website at www.irishtakeoverpanel.ie.<\/p>\n

\u2018Interests in securities\u2019 arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an \u2018interest\u2019 by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.<\/p>\n

Terms in single quotation marks are defined in the Irish Takeover Rules, which can also be found on the Panel\u2019s website. If you are in any doubt as to whether or not you are required to disclose a dealing under Rule 8, please consult the Panel\u2019s website at www.irishtakeoverpanel.ie or contact the Panel on telephone number +353 1 678 9020.<\/p>\n

\n General<\/strong>\n <\/p>\n

The release, publication or distribution of this report in or into certain jurisdictions may be restricted by the laws of those jurisdictions, including any Restricted Jurisdictions (as defined in the joint proxy statement\/prospectus). Accordingly, copies of this report and all other documents relating to the Transaction are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such Restricted Jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the proposed transaction disclaim any responsibility or liability for the violations of any such restrictions by any person.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (\u201cStrongbridge\u201d), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on\u00a0July 28, 2021, Strongbridge’s issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of\u00a0$0.01\u00a0per share. Strongbridge’s ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97. Strongbridge confirms that, as of the close of business on\u00a0July 28, 2021, there were outstanding 2,747,191 restricted … <\/p>\n

Continue reading “Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519889","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (\u201cStrongbridge\u201d), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on\u00a0July 28, 2021, Strongbridge’s issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of\u00a0$0.01\u00a0per share. Strongbridge’s ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97. Strongbridge confirms that, as of the close of business on\u00a0July 28, 2021, there were outstanding 2,747,191 restricted … Continue reading "Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T12:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue\",\"datePublished\":\"2021-07-29T12:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/\"},\"wordCount\":1875,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/\",\"name\":\"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=\",\"datePublished\":\"2021-07-29T12:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/","og_locale":"en_US","og_type":"article","og_title":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk","og_description":"DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (\u201cStrongbridge\u201d), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on\u00a0July 28, 2021, Strongbridge’s issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of\u00a0$0.01\u00a0per share. Strongbridge’s ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97. Strongbridge confirms that, as of the close of business on\u00a0July 28, 2021, there were outstanding 2,747,191 restricted … Continue reading \"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T12:18:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue","datePublished":"2021-07-29T12:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/"},"wordCount":1875,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/","name":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=","datePublished":"2021-07-29T12:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4OTI5OCM0MzIxODEyIzIwMjAwMjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-provides-announcement-under-the-irish-takeover-rules-for-relevant-securities-in-issue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519889"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}